The Allostatic Tax

The physiology of a man running above his design spec

The Opening: The Design and Its Limits

Your stress response was designed for emergencies that lasted minutes.

A predator. A physical confrontation. A sprint across open ground toward safety or away from danger. The design is elegant: cortisol floods the bloodstream, glucose rises to fuel the muscles, the heart rate accelerates, peripheral blood vessels constrict to redirect circulation toward the limbs, the immune system downregulates because tissue repair is not the priority when you are running, the digestive system quiets, the reproductive system pauses. Everything that is not immediately necessary for survival is suspended. Everything that is necessary — strength, speed, alertness — is maximally resourced.

Then the threat ends. Cortisol clears. Heart rate returns to baseline. Blood pressure normalizes. The immune system resumes its work. The digestive system restarts. Testosterone recovers. The reproductive axis, which was temporarily suppressed, resumes normal function. This is allostasis — your body loading under demand and then fully unloading when the demand resolves. The loading is not the problem. The unloading is the whole point.

The problem that kills men in midlife is not the loading. It is the failure to unload.

When the threat is a board review that doesn’t end, a fundraising round that lasts eight months, a lawsuit that moves through the system for two years, a parent dying slowly across three time zones, a marriage under sustained strain, a company that depends on your personal functioning in a way that does not allow for the ordinary maintenance of a human organism — the cortisol stays. Not at emergency-level concentrations. At a low, persistent, chronic elevation that the man himself has long since stopped noticing because it has become his physiological baseline.

This is allostatic load. And it is not metaphorical. It is measurable, in your cortisol curve, your inflammatory markers, your blood pressure, your waist circumference, your testosterone level, and — eventually — in the intima-media thickness of your carotid artery and the calcium score of your coronary arteries.

The McEwen Framework: Allostasis and Allostatic Load

In 1998, Bruce McEwen, a neuroendocrinologist at Rockefeller University, published what has become one of the most cited papers in the entire field of stress and health. In the Annals of the New York Academy of Sciences, he presented the allostatic load framework: the formal model of how the body manages chronic stress, and what happens when that management system is chronically overloaded (McEwen 1998, DOI: 10.1111/j.1749-6632.1998.tb09546.x).

McEwen identified four specific patterns of allostatic load:

1. Frequent stressor exposure: the system is activated too often without adequate recovery between activations — the man who moves from one high-stakes demand to the next without intervals of genuine physiological rest.

2. Failure to habituate: normal allostasis produces habituation to repeated similar stressors; some individuals (and particularly individuals with high chronic baseline activation) fail to habituate, maintaining elevated cortisol and sympathetic responses to stressors that should, over time, diminish in their biological impact.

3. Failure to turn off: the stress response is appropriately activated but does not return to baseline — the cortisol doesn’t clear, the blood pressure doesn’t drop back, the sympathetic tone stays elevated after the demand has resolved. This is the pattern that characterizes the man who cannot “switch off” at the end of a demanding day.

4. Inadequate response: in chronically overloaded systems, the HPA axis eventually becomes under-responsive — producing the “burnout” phenotype in which morning cortisol is blunted, the diurnal curve is flat, and the system has lost its capacity for both appropriate activation and appropriate recovery. This is not the absence of allostatic load. It is its advanced form.

The clinical significance: these are not dramatic, visible states. The man with significant allostatic load does not look burdened. He looks efficient. He looks like he’s managing. The allostatic load is invisible to observation and absent from standard clinical panels. It is present in his cortisol curve, his inflammatory markers, his visceral fat distribution, and his cardiovascular risk.

The Cortisol Curve: What It Should Look Like, and What It Doesn’t

The normal diurnal cortisol pattern has a shape as specific as a heartbeat: a sharp rise in the thirty to forty-five minutes after waking — the cortisol awakening response (CAR) — followed by a gradual decline across the morning, a flatter afternoon, and a nadir in the late evening, reaching its lowest point between midnight and 4 a.m. before beginning the next morning rise.

This curve is not merely descriptive. Each phase has a function. The morning spike facilitates metabolic and cognitive activation for the day. The gradual decline maintains appropriate arousal without excessive cardiovascular activation. The late-evening nadir creates the low-cortisol environment that facilitates sleep initiation, growth hormone secretion, and the anabolic recovery processes that are supposed to happen during sleep — including the testosterone production that occurs predominantly during the first half of the night.

In men with significant chronic stress, this curve is disrupted in characteristic ways. The morning peak blunts — reduced cortisol awakening response, which is associated with HPA axis burnout and paradoxically with higher cardiovascular risk, not lower. The evening floor rises — the nadir no longer reaches its physiologically low point, maintaining a background cortisol elevation throughout the night. The result is a flatter curve, and the flattened diurnal cortisol slope has been specifically linked to cardiovascular mortality in the Whitehall II study with high statistical significance (p = 0.0003 for the association between flat diurnal slope and cardiovascular death).

The 3 a.m. waking pattern described in Chapter 1, and the sleep architecture disruption that will be detailed in Chapter 5, are direct manifestations of this disrupted cortisol curve: the cortisol nadir is arriving too early, triggering an inappropriate morning-like arousal in the early hours of sleep, producing exactly the sympathetic activation, blood pressure elevation, and heart rate increase that represent a mini cardiovascular event replicated every night.

The man who wakes at 3:17 a.m. and finds the agenda already running is experiencing a disrupted cortisol curve. He is having a nocturnal cortisol surge in the window where cortisol should be at its lowest. It is not insomnia. It is a neuroendocrine finding.

The Vascular Tax: What Cortisol Does to Your Arteries

This is the mechanism that connects allostatic load to the cardiovascular events that are its downstream consequence. It is worth walking through in some detail because the specifics matter — they are what make this a clinical problem rather than a philosophical observation.

Endothelial function. Cortisol directly impairs endothelial nitric oxide production. The mechanism involves multiple pathways, including glucocorticoid receptor-mediated suppression of eNOS expression and increased production of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of eNOS. The result: reduced NO bioavailability, impaired vasodilation, and a shift toward the pro-inflammatory, pro-thrombotic endothelial state that is the earliest step in atherogenesis. This is the direct connection from allostatic load to the endothelial dysfunction discussed in Chapter 3.

Blood pressure. Cortisol elevates blood pressure through sodium and water retention (via mineralocorticoid receptor activation at high concentrations), through increased vascular sensitivity to catecholamines (adrenaline and noradrenaline), and through central sympathetic nervous system activation. The man whose resting blood pressure is 134/88 and whose physician attributes it to work stress is not wrong — but the attribution does not produce an action plan. The cortisol is the mechanism; the mechanism is measurable; and the blood pressure that results from chronic cortisol elevation carries a known and quantified cardiovascular risk.

Inflammation. Cortisol at acute, high concentrations is anti-inflammatory — this is the basis for corticosteroid therapy in inflammatory conditions. Cortisol at chronic, low-to-moderate elevations produces a paradoxical pro-inflammatory effect through glucocorticoid receptor desensitization: the anti-inflammatory signaling pathways become downregulated, while the pro-inflammatory pathways — NF-κB-mediated interleukin-6 and TNF-α production — become upregulated. The chronically stressed man who gets his hsCRP checked and finds it at 2.5 is experiencing this mechanism. It is a marker of arterial wall inflammation that is accelerating the atherogenic process.

Metabolic consequences. Cortisol drives visceral fat deposition through its action on glucocorticoid receptors in visceral adipocytes — particularly through the local amplification of active cortisol by the enzyme 11β-HSD1 in visceral fat depots. Visceral fat is not metabolically passive: it is an endocrine organ secreting adipokines that further promote insulin resistance, dyslipidemia, and systemic inflammation. The man who has gained fifteen to twenty pounds in the abdomen over the past decade, without major changes in diet, is very likely experiencing cortisol-driven central fat deposition as a component of his allostatic load. This is not simply a lifestyle outcome. It is a stress-hormone outcome.

The Allostatic Load Index: What It Measures

The allostatic load index, as operationalized in population-level research, is a composite of markers across four biological domains: neuroendocrine (morning cortisol, 12-hour urinary norepinephrine, DHEA-S), cardiovascular (systolic and diastolic blood pressure, resting heart rate), metabolic (waist-to-hip ratio, total cholesterol, HDL, HbA1c, albumin), and immune (hsCRP). High composite scores across these domains indicate the cumulative physiological wear of chronic stress exposure.

In 2022, Riggan and colleagues published a systematic review and meta-analysis of 17 studies examining the relationship between allostatic load and mortality in The American Journal of Preventive Medicine. Their findings: high allostatic load was associated with a 22% higher risk of all-cause mortality and a 31% higher risk of cardiovascular mortality (Riggan et al. 2022, PMID: 35393143).

These are not small effect sizes. Twenty-two percent higher all-cause mortality is a clinically meaningful risk elevation — one that, if attached to a serum biomarker, would be the subject of significant medical attention and guideline recommendations.

The critical point from the Riggan meta-analysis is one that I want to emphasize because it has direct bearing on who reads this chapter: men with the highest allostatic load scores frequently describe themselves as “managing fine.” The allostatic load index is not a measure of how stressed you feel. It is a measure of what your biology is doing. The man who has adapted to chronic stress by no longer experiencing it as distressing — who has recalibrated his baseline upward until the elevated state feels normal — is not protected from the physiological cost of that elevation. He is simply not aware of it.

This is the high-achiever’s paradox: the man who is most physiologically burdened by allostatic load is often the man who is most functionally adapted to operating under load, and therefore the man least likely to recognize the load as a clinical problem.

The Cortisol-Testosterone Inverse Relationship

The relationship between the HPA axis (the stress response system) and the HPG axis (the reproductive hormone system) is not metaphorical. It is a documented bidirectional antagonism, and understanding it changes how you interpret the fatigue, the reduced libido, the motivational blunting, and the changes in body composition that men in their forties increasingly attribute to “getting older.”

Testosterone suppresses CRH-stimulated cortisol production at the adrenal level — men with higher baseline testosterone have somewhat attenuated cortisol responses to acute stress. But the reverse relationship is what matters clinically in chronically stressed midlife men: glucocorticoids — cortisol — suppress the HPG axis through multiple mechanisms: direct inhibition of hypothalamic GnRH pulsatility, reducing the LH drive to the Leydig cells of the testes; direct Leydig cell suppression through glucocorticoid receptors; and increased hepatic SHBG production, which binds and sequester free testosterone.

The result is that the man who has been running on chronic HPA activation for years — the man described in the allostatic load framework above — is not simply experiencing age-related testosterone decline. He is experiencing chronic HPA suppression of his HPG axis on top of whatever age-related decline would have occurred anyway. This is a compound effect. The baseline decline of approximately 1% per year in serum testosterone after age thirty, documented by Harman and colleagues in a longitudinal study of the Baltimore Longitudinal Study of Aging, does not account for the stress-accelerated component. The man whose testosterone is at 285 ng/dL at forty-seven is not simply an older man. He is an older man with a functioning stress-hormone override system that has been pulling the HPG axis down for a decade.

The Travison study, a population-level analysis of three cross-sectional cohorts from the Massachusetts Male Aging Study, found that age-adjusted testosterone levels in American men declined approximately 1.2% per year between 1987 and 2004 — meaning a man born in 1970 had 17% lower testosterone at any given age than a man born in 1940 (Travison et al. 2007, PMID: 17062768). This population-level decline exceeds what age alone accounts for. Chronic stress, sleep deprivation, and sedentary behavior — all of which have increased over the same period — are the most plausible contributors.

Tsigos and Chrousos, in a 2002 review in the Journal of Psychosomatic Research, documented the HPA-HPG interaction formally: glucocorticoids suppress testosterone production at multiple levels of the reproductive axis, and the net result in chronically stressed men is a compound endocrine suppression (Tsigos & Chrousos 2002). Viau, in a 2002 review in the Journal of Neuroendocrinology, provided the detailed mechanistic evidence for the bidirectional cross-talk, confirming that the two axes do not operate independently but in a state of mutual regulation — and mutual competition under chronic stress conditions (Viau 2002).

The practical clinical translation: the man who complains of fatigue, reduced motivation, difficulty sleeping, and changed sexual function who is told his testosterone is “normal” at 310 ng/dL should be asked what his cortisol is doing — because a testosterone level that is technically within the reference range, in the context of a chronically activated HPA axis, is a testosterone level that is being actively suppressed. Treating the testosterone without addressing the upstream suppressor is, to use a plumbing metaphor, mopping the floor without turning off the tap.

The High-Achiever’s Paradox: The Man Who Doesn’t Know He’s Stressed

Cortisol and the Immune System: The Inflammation Mechanism

There is a pathway in the allostatic load cascade that I want to describe with some care, because it is often the least visible component of the process and one of the most clinically significant: the relationship between chronic cortisol elevation and the immune system’s contribution to atherosclerosis.

Cortisol is, in its acute form, anti-inflammatory. This is why corticosteroids — synthetic glucocorticoids — are used to treat inflammatory conditions ranging from asthma to rheumatoid arthritis. The acute anti-inflammatory action of cortisol is well-established and well-utilized in medicine.

The paradox — and it is a physiological paradox, not a philosophical one — is that chronic low-to-moderate cortisol elevation produces the opposite effect. Prolonged glucocorticoid exposure leads to glucocorticoid receptor downregulation and reduced receptor sensitivity in immune cells. The cells that would normally respond to cortisol’s anti-inflammatory signal by quieting down become progressively resistant to that signal. Meanwhile, the pro-inflammatory nuclear factor-kappa B (NF-κB) pathway — which cortisol normally suppresses — escapes this dampening and becomes upregulated. The result: chronically elevated inflammatory cytokines, particularly interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), in the very man whose cortisol levels might appear modestly elevated rather than dramatically so.

This inflammatory state has a direct atherogenic consequence. IL-6 produced in adipose tissue and by immune cells circulates to the liver, stimulating the production of C-reactive protein (hsCRP) and fibrinogen, both of which are inflammatory markers associated with cardiovascular risk. More directly, the pro-inflammatory cytokines produced by the activated immune system reach the arterial wall, activating adhesion molecules on the endothelial surface, facilitating the attachment of circulating monocytes, and initiating the foam cell formation that is the earliest structural step in atherosclerotic plaque development.

The man whose hsCRP is 2.5 mg/L is not experiencing a minor laboratory anomaly. He is experiencing measurable arterial wall inflammation driven, at least in part, by the glucocorticoid resistance cascade of his chronically activated stress response system. His arteries are inflamed. That inflammation is accelerating the deposition of plaque that the Framingham risk score is not yet reflecting as a major elevation in 10-year risk.

From a review by Slusher and Acevedo published in Frontiers in Physiology in 2023: the HPA and sympathoadrenal systems activate NF-κB-mediated inflammation that produces endothelial dysfunction through precisely this pathway — chronic stress → HPA activation → glucocorticoid resistance → sustained NF-κB signaling → endothelial activation and atherogenesis (Slusher & Acevedo 2023, PMC10065149). This is the biological thread connecting the chronic stress of professional life to the arterial wall changes that are silent until they are not.

The Sleep-Cortisol-Testosterone Triad

I want to briefly preview Chapter 5 here, because the sleep story and the cortisol story are not parallel — they are the same story told in two registers.

Seventy percent of daily testosterone secretion occurs during sleep, predominantly during slow-wave (Stage 3) sleep and the first half of the night. The cortisol nadir that allows this testosterone secretion to proceed normally occurs during the same window — the late-evening and early-night period when cortisol should be at its lowest. When cortisol is chronically elevated and the diurnal nadir is raised, the permissive window for testosterone secretion is compressed. The man who has been on the HPA-activation pattern for years is producing less testosterone partly because he never reaches the cortisol low that allows the testosterone production to proceed normally.

Sleep deprivation compounds this. Liu and colleagues, in a 2022 comprehensive review in Reviews in Endocrine and Metabolic Disorders, documented the integrated relationship: sleep loss and disrupted architecture are associated with lower morning, afternoon, and 24-hour testosterone plus higher afternoon cortisol (Liu et al. 2022, PMC9510302). These reciprocal changes impair anabolic-catabolic signaling across multiple metabolic systems simultaneously. The man who is chronically sleep-deprived is not simply tired. He is in a compound endocrine suppression state — low testosterone, elevated afternoon cortisol, elevated inflammatory markers, impaired insulin sensitivity — all of which are downstream consequences of the same allostatic overload.

This triad — cortisol excess, sleep disruption, testosterone suppression — is the biochemical portrait of the man described at the beginning of this chapter. It is not inevitable with age. It is the consequence of a physiological system that has been chronically loaded without adequate recovery. And it is measurable, modifiable, and addressable.

I want to address a specific psychological phenomenon that I see regularly in the men who walk into my office: the man who genuinely does not identify as stressed.

He is not in denial. He does not feel stressed in the way the word usually implies — anxious, overwhelmed, unable to cope. He is functioning at a high level. He is productive, clear-headed in the ways that matter professionally, capable of sustained effort and complex decision-making. When asked if he is under stress, he answers honestly: “Not particularly.” He means it.

What he has done, over many years, is recalibrate his baseline. The autonomic activation that would have felt like stress at twenty-five now feels like normal operating mode. The elevated resting heart rate, the shortened sleep, the sustained cortisol elevation, the cardiovascular hyperreactivity — these have become his physiological landscape, no longer experienced as states he is in but simply as the way he is. He is not managing stress. He is the stress, metabolically speaking.

The clinical consequence: the allostatic load index measures what his biology is doing, not what he feels. His morning cortisol is blunted (HPA burnout pattern). His hsCRP is 2.3 (chronic low-grade inflammation). His waist circumference is 39.5 inches (central adiposity from cortisol-driven visceral fat deposition). His resting heart rate is 74. His blood pressure is 135/86. His testosterone is 295.

He feels fine. His biology is telling a different story.

The Epel and colleagues 2018 review in Frontiers in Neuroendocrinology addressed exactly this problem: the discordance between subjective stress experience and objective physiological stress markers is common, particularly in high-functioning adults who have chronically adapted to high-demand environments (Epel et al. 2018). The implication for clinical practice: subjective self-report of stress is not a reliable measure of allostatic load. The biology needs to be measured directly.

The Body’s Bill Collection Process: How Allostatic Load Becomes Disease

The trajectory from chronic stress exposure to cardiovascular disease moves through several recognized intermediate stages, each of which is measurable, each of which is modifiable, and each of which represents a point at which intervention changes the downstream outcome.

Stage 1 — Dysregulated cortisol curve: The diurnal cortisol pattern flattens. Morning peak blunts. Evening floor rises. The cascade begins. This is measurable with a four-point salivary cortisol collection (morning, midday, afternoon, evening) and is the earliest physiological signal of allostatic load. Most men at this stage feel slightly more tired than usual and attribute it to schedule.

Stage 2 — Early metabolic changes: Visceral fat begins accumulating. Insulin sensitivity starts to decline. Fasting glucose drifts upward toward prediabetic range. ApoB rises as VLDL production increases. hsCRP climbs into the 1-3 range. Blood pressure is consistently in the 130s over 80s. Testosterone begins declining faster than age alone predicts. This stage is detectable on laboratory testing and is entirely reversible with the appropriate interventions. Most men at this stage are told their labs are “borderline” or “normal” and are not offered a management plan.

Stage 3 — Established metabolic syndrome: Three or more of the five components — elevated waist circumference, elevated fasting glucose, elevated triglycerides, reduced HDL, elevated blood pressure — are present. Metabolic syndrome affects more than 35% of American men in the 40-59 age range, and it represents a point at which the allostatic load has produced structural metabolic changes that require active management.

Stage 4 — Vascular consequences: Endothelial dysfunction is established. Subclinical atherosclerosis is measurable on CAC scoring. Carotid intima-media thickness is increased. This is the stage at which the sentinel events described in Chapter 3 — the erectile dysfunction, the 3 a.m. waking, the blood pressure that doesn’t normalize — have been present for some time and have been explained away.

Stage 5 — Clinical cardiovascular disease: The cardiovascular event. The acute coronary syndrome, the stroke, the serious arrhythmia. By this stage, the chain that began with the cortisol curve disruption has been running for five to fifteen years.

The reason this trajectory matters is not to frighten. It is to locate. The man reading this chapter is almost certainly somewhere in Stages 1 through 3. He may have early findings consistent with Stage 4. He is not at Stage 5 yet. The interventions that matter most are the ones implemented in Stages 1 through 3, and those interventions are specific, evidence-based, and will be described in full in Chapter 12.

What You Can Measure

The standard cardiovascular panel — total cholesterol, LDL, HDL, triglycerides, blood glucose — does not measure allostatic load directly. But several components of the allostatic load index are available as routine laboratory tests, and a targeted panel provides enough information to understand the current state of the system.

Morning serum cortisol: A single morning cortisol (drawn before 9 a.m.) provides a snapshot. A blunted morning cortisol below 10 mcg/dL suggests HPA axis burnout. This is not the same as an elevated cortisol — it is the flattened, post-burnout pattern of a chronically overloaded system. More informative is the four-point salivary cortisol test (morning, noon, 4 p.m., bedtime), which maps the diurnal curve and identifies the flat-slope pattern most strongly associated with cardiovascular risk.

High-sensitivity CRP (hsCRP): A measure of systemic inflammation. Values below 1.0 mg/L are low risk; 1.0–3.0 is intermediate risk; above 3.0 is high risk in the JUPITER trial stratification framework. In the context of the allostatic load discussion, hsCRP is measuring one of the downstream consequences of chronic cortisol elevation — the glucocorticoid resistance-mediated shift toward pro-inflammatory cytokine production.

Fasting insulin and glucose: The metabolic consequence of cortisol-driven insulin resistance appears early in the fasting insulin level — often elevated before fasting glucose moves out of the normal range. A fasting insulin above 8 mIU/L in a non-diabetic man suggests early insulin resistance. This is not routinely ordered on standard metabolic panels; you will need to ask specifically.

Waist circumference: The cheapest allostatic load proxy available. A waist circumference above 40 inches in a man is associated with visceral adiposity and the entire downstream metabolic cascade. This measurement takes ten seconds, costs nothing, and correlates with cardiovascular risk independent of BMI. It is not routinely measured at most clinical encounters.

Testosterone: The HPG axis output, which is suppressed by chronic HPA activation. A morning testosterone (drawn before 10 a.m.) reflects the HPA-HPG interaction and the compound effect of age and stress on the reproductive axis.

These measures together — cortisol curve, hsCRP, fasting insulin, waist circumference, testosterone — provide a functional allostatic load profile. They are ordinary laboratory tests. None of them require a specialist. All of them require asking.

Clinical Pearl — If you read nothing else in this chapter:

A 2022 systematic review and meta-analysis of 17 studies found that high allostatic load — the accumulated physiological wear from chronic stress — is associated with a 22% higher risk of all-cause mortality and a 31% higher risk of cardiovascular death. These are not small numbers. And the critical point: allostatic load is not measured by how stressed you feel. It is measured by what your cortisol, blood pressure, waist circumference, inflammatory markers, and metabolic panel actually show. Men with the highest allostatic load scores often describe themselves as “managing fine.” The biology does not confirm their self-assessment (Riggan et al. 2022, PMID: 35393143).

A Composite Clinical Portrait

James is fifty-two. He runs the African division of a multinational financial services firm. He has lived on two continents in the past decade — London, then New York, then Nairobi for three years, now back in Newark. Each transition has required the construction of a new professional identity in a new environment, the re-establishment of relationships, the management of systems he doesn’t fully control from a position he has to earn repeatedly.

He is excellent at all of this. He is also tired in a way he hasn’t fully named.

His resting blood pressure at our first encounter is 148/96. He is surprised — he says his blood pressure was fine at his last check, eighteen months ago. I ask where the last check was done. A pharmacy kiosk at Heathrow, he says, between flights. I explain that automated pharmacy kiosks are not ideal cardiovascular laboratories.

His waist circumference is 41.5 inches. He runs occasionally when travel allows. His weight is up about twelve pounds from where it was five years ago, mostly in the middle. He attributes this to age and travel and the way things are right now. He is correct that those factors are involved.

His morning cortisol is 8.4 mcg/dL — low-normal, consistent with HPA burnout-phase blunting. His hsCRP is 3.1. His fasting insulin is 11.4. His testosterone is 268 ng/dL. His ApoB is 124. His CAC score is 48 — early calcification, at fifty-two, in a man whose last physician told him his labs were fine.

He is a man running above his design spec. He has been doing it for twenty years. His body is presenting the bill, in the language of numbers. The numbers are payable. But only if you check them.

The Permission Paragraph

The word “stress” has been so thoroughly absorbed into the vocabulary of the manageable — “I’m a bit stressed,” “stress and I get along,” “everyone is stressed” — that it has largely lost its standing as a medical concept. I want to restore it.

What you have been calling “just the way things are” is, in the bodies of the men I see every week, showing up as elevated hsCRP, disrupted cortisol curves, rising fasting insulin, and carotid intima-media thickness that has been quietly increasing for years. It is showing up in testosterone levels that have been suppressed for longer than the age-related trajectory predicts. It is showing up in blood pressure that is always slightly too high and always attributed to something that happened recently.

You are not required to find any of this distressing. You are not required to reduce your ambition, change your career, or become a different kind of man. You are required only to take it seriously enough to measure it, and to act on what the measurements show.

The cortisol that is damaging your endothelium does not know whether you have acknowledged it. It is doing its work regardless. The question is whether you will do yours.

What to Do This Week

1. Ask your physician for the following tests at your next appointment, if they haven’t been ordered recently: hsCRP, fasting insulin (not just fasting glucose), ApoB, morning testosterone (drawn before 9 a.m.), and a morning cortisol. These are standard laboratory tests available at any clinical laboratory. They are not expensive. Together, they give you and your physician a working picture of your allostatic load.

2. Measure your waist circumference. Use a tape measure, at the level of your navel, after breathing out. Write the number down. A measurement above 40 inches in a man is a clinical finding. This is information, not judgment.

3. This week, for one day, notice when you use “it’s fine” or “I’m managing” to close a conversation — with yourself, with a colleague, with someone who asks how you’re doing. Not to change the answer. Just to notice how automatic it is, and whether there is, behind the automatic answer, something that hasn’t been fully accounted for.

There is one place where allostatic load announces itself loudly and men still miss it: the hours between midnight and 5 a.m. Chapter 5 is about what your body is doing while you lie there, eyes open, with the agenda already running — and why what you’ve been calling insomnia is, in at least half the men who describe this pattern, something more specific and more clinically significant.

— End of Chapters 1–4 —

A Note on Citations

All primary citations in these four chapters are drawn from the architecture’s Master Primary Source Reference and the connected deterioration chain evidence dossier, both prepared for Stop Dying Early. Citations are provided as inline markdown links following the format established in the architecture document.

Chapter 1 primary citations:

• Kauhanen et al. 1996, PMID: 9032717 — Alexithymia and risk of death, Journal of Psychosomatic Research
• Vadini et al. 2024, PMC11654074 — Alexithymia and 10-year CVD risk, Frontiers in Psychology
• Chapman et al. 2013, Harvard DASH — Emotion suppression and 12-year mortality
• Inman et al. 2009, PMC2664580 — ED preceding coronary artery disease, Mayo Clinic Proceedings

Chapter 2 primary citations:

• Chapman et al. 2013, Harvard DASH — Emotion suppression and mortality
• Kauhanen et al. 1996, PMID: 9032717 — Alexithymia and mortality
• Holt-Lunstad et al. 2015, DOI: 10.1177/1745691614568352 — Loneliness and social isolation as risk factors for mortality
• Appleton et al. 2014, PMC4251797 — Emotion regulation and Framingham CVD risk

Chapter 3 primary citations:

• Vlachopoulos et al. 2013, DOI: 10.1093/eurheartj/eht112 — ED and cardiovascular events meta-analysis, European Heart Journal
• Gandaglia et al. 2014, DOI: 10.1016/j.eururo.2013.08.023 — ED and cardiovascular disease systematic review, European Urology
• Vlachopoulos et al. 2021, PMC8161068 — ED as hallmark of cardiovascular disease, Journal of Clinical Medicine
• Corona et al. 2022, PMC9405076 — Endothelial dysfunction and ED, Biomedicines
• Köhler et al. / Princeton IV 2024, DOI: 10.1016/j.mayocp.2024.06.002 — Princeton IV Consensus, Mayo Clinic Proceedings
• Inman et al. 2009, PMC2664580 — ED and incident CAD, Olmsted County cohort
• Laughlin et al. 2008, DOI: 10.1210/jc.2007-1792 — Low testosterone and mortality

Chapter 4 primary citations:

• McEwen 1998, DOI: 10.1111/j.1749-6632.1998.tb09546.x — Allostatic load framework, Annals of the New York Academy of Sciences
• Riggan et al. 2022, PMID: 35393143 — Allostatic load and mortality meta-analysis
• Tsigos & Chrousos 2002 — HPA axis and stress, Journal of Psychosomatic Research
• Viau 2002 — HPA-HPG cross-talk, Journal of Neuroendocrinology
• Epel et al. 2018 — Stress measurement frameworks, Frontiers in Neuroendocrinology
• Travison et al. 2007, PMID: 17062768 — Population-level testosterone decline